Steris

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Cantel Medical Corp. Buyout

Thursday, January 14, 2021 - 12:30am

announces that it is investigating Cantel Medical Corp. (Cantel) (NYSE: CMD ) regarding possible breaches of fiduciary duties and other violations of law related to Cantels agreement to be acquired by STERIS plc (STERIS) (NYSE: STE ).

Key Points: 
  • announces that it is investigating Cantel Medical Corp. (Cantel) (NYSE: CMD ) regarding possible breaches of fiduciary duties and other violations of law related to Cantels agreement to be acquired by STERIS plc (STERIS) (NYSE: STE ).
  • Under the terms of the agreement, Cantels shareholders will receive approximately $16.93 in cash and 0.33787 of a share of STERIS per share.
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cantel-medical-corp .
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com .

CANTEL MEDICAL INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cantel Medical Corp - CMD

Thursday, January 14, 2021 - 12:27am

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Cantel Medical Corp (NYSE: CMD) to STERIS plc (NYSE: STE).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Cantel Medical Corp (NYSE: CMD) to STERIS plc (NYSE: STE).
  • Under the terms of the proposed transaction, shareholders of Cantel will receive only $16.93 in cash and 0.33787 of a STERIS ordinary share for each share of Cantel that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

CANTEL ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CMD and Encourages Investors to Contact the Firm

Tuesday, January 12, 2021 - 5:21pm

On January 12, 2021, Cantel announced that it had signed an agreement to be acquired by STERIS for approximately $4.6 billion.

Key Points: 
  • On January 12, 2021, Cantel announced that it had signed an agreement to be acquired by STERIS for approximately $4.6 billion.
  • Pursuant to the merger agreement, Cantel stockholders will receive $16.93 in cash and 0.33787 shares of STERIS common stock for each share of Cantel common stock owned.
  • The deal is scheduled to close by the end of STERISs first quarter of fiscal 2022 (ending June 30, 2021).
  • Bragar Eagel & Squire is concerned that Cantels board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.

STERIS Announces Definitive Agreement to Acquire Cantel Medical

Tuesday, January 12, 2021 - 12:12pm

Further information can be found in the Annual Report on Form 10-K of Cantel.

Key Points: 
  • Further information can be found in the Annual Report on Form 10-K of Cantel.
  • This communication contains forward-looking statements within the meaning of the federal securities laws about STERIS, Cantel and the proposed transaction.
  • In connection with the proposed transaction, STERIS will file a registration statement on Form S-4 with the Securities and Exchange Commission (the SEC).
  • STERIS, Cantel and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.

STERIS To Participate in Upcoming Investor Conferences

Thursday, January 7, 2021 - 10:14pm

Other risk factors are described in STERISs other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2020.

Key Points: 
  • Other risk factors are described in STERISs other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2020.
  • Many of these important factors are outside of STERISs control.
  • References to products are summaries only and should not be considered the specific terms of the product clearance or literature.
  • Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.

2020 On-site Mobile Clinic Achieves Excellent Air Quality and Professional Standards with STERIS and Emmes Optym Certification

Thursday, January 7, 2021 - 4:38pm

2020 On-site , Boston-based provider of mobile vision care services for more than 350 corporate clients and thousands of patients, is the first mobile clinic in the industry to receive certifications from Emmes Optym and STERIS for excellent air quality, COVID-19 protocols and professional standards.

Key Points: 
  • 2020 On-site , Boston-based provider of mobile vision care services for more than 350 corporate clients and thousands of patients, is the first mobile clinic in the industry to receive certifications from Emmes Optym and STERIS for excellent air quality, COVID-19 protocols and professional standards.
  • In preparation for specific scientific programs, two 2020 On-site mobile vision clinics were modified to meet Emmes Optym and STERIS protocols.
  • Its test collected samples throughout the 2020 On-site facility to detect any abnormal bacterial and fungal growth, which resulted in a passing, five-star air quality analysis.
  • The Emmes Optym certification proves we can provide the exact same stringent clinical service and testing environment a brick & mortar clinic can, on our Mobile Vision Clinics.

STERIS Completes Acquisition of Key Surgical

Wednesday, November 18, 2020 - 9:30pm

Other risk factors are described in STERISs other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2020.

Key Points: 
  • Other risk factors are described in STERISs other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2020.
  • Many of these important factors are outside of STERISs control.
  • References to products are summaries only and should not be considered the specific terms of the product clearance or literature.
  • Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.

STERIS to Host a Conference Call for Fiscal 2021 Second Quarter Financial Results on November 3, 2020

Tuesday, October 20, 2020 - 12:00pm

Other risk factors are described in STERISs other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2020.

Key Points: 
  • Other risk factors are described in STERISs other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2020.
  • Many of these important factors are outside of STERISs control.
  • References to products are summaries only and should not be considered the specific terms of the product clearance or literature.
  • Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.

Frequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors

Friday, September 25, 2020 - 2:00pm

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the bodys innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Cynthia Feldmann to its Board of Directors.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the bodys innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Cynthia Feldmann to its Board of Directors.
  • Ms. Feldmann is an experienced finance and accounting professional who brings to Frequency several decades of experience in life sciences and public company board leadership.
  • Currently, she is a member of the board of directors at STERIS PLC (NYSE: STE) and at UFP Technologies (NASDAQ: UFPT).
  • Cynthia is a great addition and will provide tremendous perspective having worked as an independent board member for newly-public companies and contributing to their success over time, said Marc A. Cohen, chairman of the board of directors at Frequency Therapeutics.

$2.5 Bn Operating Room Integration Market by Component, Application, End Use, Device and Region - Forecast to 2026

Monday, August 24, 2020 - 10:45pm

DUBLIN, Aug. 24, 2020 /PRNewswire/ -- The "Global Operating Room Integration Market By Component, By Application, By End Use, By Devices, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 24, 2020 /PRNewswire/ -- The "Global Operating Room Integration Market By Component, By Application, By End Use, By Devices, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Operating Room Integration Market size is expected to reach $2.5 billion by 2026, rising at a market growth of 10.6% CAGR during the forecast period.
  • Based on the Analysis presented in the Cardinal matrix, Canon, Inc., Stryker Corporation, and Steris PLC are the forerunners in the Operating Room Integration Market.
  • Following this agreement, the former company has been supplying the agency with integrated operating room components, accessories, and services.